GLP-1 Drugs Show promise for Weight Loss, But Concerns Over Industry Influence Remain
The World Health Association (WHO) is poised to issue new guidelines on obesity treatment informed by recent cochrane reviews indicating that a class of drugs known as GLP-1 receptor agonists can lead to significant weight loss, though questions linger regarding the objectivity of research due to heavy pharmaceutical industry involvement.
new analyses evaluated three prominent GLP-1 drugs – tirzepatide, semaglutide, adn liraglutide – and found each demonstrably effective in promoting weight loss compared to placebo. However, researchers caution that long-term safety data, potential side effects, and the impact of financial conflicts of interest require further inquiry.
From Diabetes Treatment to Weight Management
Initially introduced in the mid-2000s to manage type 2 diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have proven effective in improving blood sugar levels, reducing complications, aiding weight reduction, and even lowering the ris
Tirzepatide, administered weekly, resulted in approximately a 16% reduction in body weight after 12 to 18 months. Data from eight randomized controlled trials involving 6,361 participants suggest these effects could last up to 3.5 years, though thorough long-term safety data are still lacking.
Semaglutide, also injected weekly, was associated with an average weight loss of around 11% after 24 to 68 weeks, with evidence indicating the effect may persist for up to two years based on 18 randomized controlled trials encompassing 27,949 participants. While more patients achieved at least a 5% weight reduction, the drug was also linked to higher rates of mild-to-moderate gastrointestinal issues.
Liraglutide, a daily injection, yielded an average 4-5% weight loss in 24 trials involving 9,937 participants, still demonstrating superior results compared to placebo. Evidence of benefits extending beyond two years was more limited.
The reviews found no significant difference between the drugs and placebo regarding major cardiovascular events, mortality, or quality of life.However, nausea and digestive discomfort were reported more frequently among those taking GLP-1 drugs, leading some participants to discontinue treatment due to these side effects.
“These drugs have the potential to bring about significant weight loss, notably in the first year,” stated a co-lead researcher from Heinrich heine University Düsseldorf, germany. “It’s an exciting moment after decades of unsuccessful attempts to find effective treatments for people living with obesity.”
Concerns Over Funding and Global Access
A significant concern raised by the reviews is the pervasive influence of pharmaceutical companies. Most studies were funded by the manufacturers of these drugs and were shaped by them in terms of design, analysis, and reporting, raising questions about potential conflicts of interest. This underscores the critical need for independent research to validate these findings.
The authors also emphasized that access, affordability, and insurance coverage must be addressed to prevent exacerbating existing health inequities. Costs remain a substantial barrier, particularly for semaglutide and tirzepatide, even though liraglutide has become more affordable as its patent expired. Semaglutide’s patent is scheduled to expire in 2026.
furthermore, the majority of trials were conducted in middle- and high-income countries, with limited portrayal from regions like Africa, Central America, and Southeast Asia. Researchers stress the importance of understanding how these drugs perform in diverse populations,given variations in body composition,eating patterns,and health behaviors worldwide.
“We need more data on the long-term effects and other outcomes related to cardiovascular health, particularly in lower-risk individuals,” explained a co-lead researcher from the Universidad de Valparaíso, Chile. “Weight regain after stopping treatment may affect the long-term sustainability of the observed benefits. More independent studies from a public health perspective are needed.”
The reviews highlight the urgent need for long-term, independent investigations to inform clinical and policy decisions and to fully define the role of GLP-1 receptor agonists in achieving lasting weight management. These findings will directly contribute to upcoming WHO guidelines on the use of GLP-1 receptor agonists for obesity treatment.
